menu
    • menu
    [{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"WEP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ WEP","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Therapeutics \/ WEP"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Nabriva","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Therapeutics \/ Nabriva"},{"orgOrder":0,"company":"Sinovant Sciences","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovant Sciences \/ Nabriva Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Sinovant Sciences \/ Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Lefamulin Acetate","moa":"Peptidyl transferase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nabriva Therapeutics \/ Er-Kim","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Therapeutics \/ Er-Kim"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"Peptidyl transferase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lefamulin Acetate

    Menu

    Lefamulin Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult...

                            Details : XENLETA (lefamulin) is first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required...

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 28, 2022

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients ...

                            Details : Xenleta (lefamulin) is a novel, first-in-class, IV and oral pleuromutilin antimicrobial agent that has been demonstrated to be highly potent against S. aureus, including MRSA and strains obtained from patients with CF.

                            Brand Name : Xenleta

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 11, 2022

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nabriva Therapeutics Expands XENLETA (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

                            Details : Under the terms of the agreement, Er-Kim gains exclusive rights to distribute XENLETA (lefamulin) in the following countries: Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia.

                            Brand Name : Xenleta

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 18, 2022

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA (lefamulin) in Adult Patient...

                            Details : XENLETA has the potential to provide a well-tolerated oral and intravenous anti-MRSA treatment option with a novel mechanism for this difficult to treat patient population. We look forward to sharing the results of this study with the medical community.

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 11, 2022

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

                            Details : Sumitomo filed NDA to market oral and IV formulations of lefamulin,first systemic pleuromutilin antibiotic for the treatment of community-acquired pneumonia in adults in mainland China.

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 29, 2021

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (Lefamulin)

                            Details : XENLETA is the first intravenous and oral pleuromutilin approved for the systemic treatment of community acquired bacterial pneumonia (CABP) in adults, and also reduced pro-inflammatory cytokines comparable to that observed with dexamethasone.

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2021

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nabriva Therapeutics to Present Data at IDWeek 2021

                            Details : XENLETA® (lefamulin) is first-in-class pleuromutilin antibiotic for treatment of community-acquired bacterial pneumonia (CABP). It's in vitro activity of lefamulin against Staphylococcus aureus isolated from lower respiratory tract of children with cyst...

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 24, 2021

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sinovant Sciences

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Sinovant Sciences

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Nabriva Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin i...

                            Details : Sinovant’s multi-center, randomized, double-blind trial was designed to evaluate the safety and efficacy of intravenous (IV) to oral lefamulin compared to IV/oral moxifloxacin in 125 subjects with CABP.

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2021

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Nabriva Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Nabriva Therapeutics

                            Deal Size : $101.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Ba...

                            Details : The restructured agreement provides for additional manufacturing collaboration and regulatory support [to be provided to Sinovant by Nabriva] that is expected to help expedite the delivery of XENLETA to patients in greater China.

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : $5.0 million

                            December 07, 2020

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Nabriva Therapeutics

                            Deal Size : $101.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial P...

                            Details : Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes

                            Brand Name : Xenleta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 13, 2020

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth